Cytomegalovirus (CMV) pneumonia is a very rare but often fatal complication of autologous bone marrow or peripheral blood progenitor cell transplantation. Diagnosis is usually made by means of CMV antigenemia which is strongly predictive of CMV disease. We describe two cases of PBPC transplantation who survived after CMV pneumonia which was diagnosed only by bronchoalveolar lavage in the absence of CMV-antigenemia.
Cytomegalovirus (CMV) is an important cause of disease in patients receiving allogeneic bone marrow transplantation (BMT). 1 Patients receiving autologous BMT have a low incidence of CMV infection and disease. 2 However, in spite of this low rate of disease, CMV pneumonia represents a rare but often fatal complication following autologous BMT, and is generally observed a median of 100 days after transplantation. 3 In these cases the radiological picture is generally represented by bilateral interstitial involvement of the lungs which develops in the lower pulmonary fields and subsequently spreads to both the parenchymas, even though nodular or localized patterns have been reported. 4 Detection of early CMV-antigen in peripheral blood cells by means of anti-pp65 antigen monoclonal antibodies represents a well known, significant tool for diagnosis of CMV infection that can lead to CMV disease. 5 The detection of CMV by bronchoalveolar lavage (BAL) is also significant for the diagnosis of CMV pneumonia. 4, 6 Patients and materials Genova, Italy. Peripheral blood progenitor cells (PBPC) were reinfused in 83 patients.
The overall incidence of documented CMV pneumonia among recipients of an autologous transplant was 2/296, both of whom were in the PBPC subgroup (incidence rate of 2.4% for PBPC recipients).
These two cases of CMV pneumonia occurring 7 and 11 days after PBPC transplantation (PBPCT) are reported in this paper.
Case report 1
PM, a 4-year-old male affected by disseminated neuroblastoma, serologically positive for CMV, was admitted to the BMT Unit in August 1995, in order to receive high-dose therapy with cyclophosphamide 200 mg/kg plus melphalan 140 mg/m 2 followed by 1.8 ϫ 10 6 /kg CD34 ϩ PBPC rescue as consolidation of a very good partial remission obtained with six cycles of polychemotherapy and surgical removal of the abdominal, primary tumor. On day ϩ7 the patient developed fever Ͼ38°C, mild tachypnea (respiration rate, 40/min) with a rapid worsening the following day (respiration rate, 75/min) associated with severe dyspnea. At that time the total white blood cell count (WBC) was of 0.1 ϫ 10 9 /l. Chest X-ray showed peribronchial thickening without pleuroparenchymal lesions. CMV antigenemia was negative, probably due to the very low number of WBC.
BAL was performed and CMV was detected from a sample taken by means of this procedure. The patient received treatment with Foscarnet 90 mg/kg twice daily for 14 days and intravenous aspecific immunoglobulins 500 mg/kg/day for 5 days, with rapid improvement of his clinical condition.
Case report 2
MF, a 3-year-old female patient suffering from disseminated neuroblastoma, was admitted to our BMT Unit in August 1995 to receive a second course of high-dose therapy with busulphan 16 mg/kg, VP16 80 mg/kg and thiotepa 10 mg/kg followed by PBPC rescue (9.8 ϫ 10 Metaiodobenzil-guanidine to treat the inoperable residual abdominal tumor. The infectious and hepato-renal toxicity of these treatments was mild and only persistent thrombocytopenia (38 ϫ 10 9 /l) was present. On day ϩ11 after transplant, besides persistent high fever and severe oral mucositis, she showed poly-dyspnea and a chest X-ray showed decreased transparency of the right lung, without any sign of disease in the left one (Figure 1) . The peripheral count was as follows: WBC, 2.3 ϫ 10 9 /l; neutrophils, 23%; monocytes, 17% and lymphocytes 60%. BAL performed on day ϩ13 revealed the massive presence of CMV-positive cells, in the presence of persistently negative CMV-antigenemia. Therapy with gancyclovir 10 mg/kg/day for 15 days as well as high-dose non-specific immunoglobulins (500 mg/kg/day for 5 days), promptly resolved the respiratory distress and radiologic pictures.
CMV-antigenemia was positive in a third patient 17 days after developing pneumonia. In this case no diagnostic procedure could be carried out on the lungs (neither BAL nor autopsy afterwards) and therefore pneumonia could not be clearly attributed to CMV.
Discussion
Our experience confirms that CMV pneumonia is rare among patients receiving autologous BMT, including PBPC transplantation, with an overall incidence of 1% and a 2.4% incidence among those receiving PBPC.
In pneumonia cases of patients receiving PBPC the virus was detected in BAL, but not in the peripheral blood cells. In the first case, this was due to the low WBC count present at the time of pneumonia. In the second case, the radiological picture was unusual since massively decreased transparency of the right lung was seen, though with no sign of disease in the left one. Both patients received combined therapy with antiviral drugs and immunoglobulins, as proposed for patients with CMV pneumonia after allogeneic BMT, 7 and survived. Our choice of anti-CMV drug was made on the basis of the individual hematological situation (Gancyclovir for the patient with leukocyte recovery, foscarnet for the neutropenic child).
It is well known that detection of CMV in the peripheral blood after allogeneic 8 or autologous 9 BMT is strongly correlated with the development of CMV disease. CMV antigenemia generally becomes positive 21-35 days after allogeneic BMT 5 or after a median of 33 days following autologous BMT.
9 CMV-antigenemia is evaluated by means of pp65-positive polymorphonuclear cells. The antigen detected represents a structural protein of CMV and positive leukocytes may represent truly infected cells. The identification of even one positive-staining cell denotes the presence of active CMV infection. Since the first step towards CMV-antigen detection is isolation and cytocentrifugation of peripheral blood leukocytes, followed by immunoperoxidase staining by monoclonal antibodies and lastly counting the number of positive cells, it is clear that the sensitivity of the procedure is strictly related to the number of peripheral blood leukocytes. Therefore, the presence of neutropenia (such as was observed in our first patient) reduces the usefulness of this diagnostic procedure. Polymerase chain reaction (PCR) represents an attractive diagnostic tool in this kind of situation. However, the low incidence of CMV disease after autologous BMT or PBPCT, as well as the high cost and technical complexity of this test probably does not justify its routine use in these patients.
In conclusion, our experience shows that when pneumonia develops during pre-engraftment neutropenia, or when any kind of pneumopathy is seen after BMT, a search for CMV should be carried out both by BAL and in the blood. Patients with positive cultures should be treated with antiviral drugs and immunoglobulins which might represent effective tools for treating this complication, even when dealing with autologous transplant patients.
